CloudBlue and CloudSense Strike a Strategic Relationship to Connect Telecommunications Providers With a Broad Ecosystem of ICT Channel Partners via a New Digital Catalog
5.4.2022 16:00:00 EEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company which powers some of the largest commerce platforms for cloud and IT channel products globally, today announced an agreement with CloudSense, provider of one of the market’s most powerful Configure, Price, Quote (CPQ) platforms.
CloudSense has a well-established footprint within the telecommunications industry, with customers including prominent regional and international brands such as BT, Starhub and Vodafone Ziggo. By providing a direct integration from CloudBlue Connect™ to the CloudSense CPQ platform, CloudSense’s community of telecommunications customers will be able to tap into a new pool of ICT offerings and scale their business faster than ever.
The direct integration between CloudBlue Connect and CloudSense CPQ will allow telecommunications providers to enrich their own portfolio of B2B solutions more efficiently. This new integration will streamline their ability to procure traditional ICT services and bundle them into a wide range of innovative B2B XaaS solutions, which can be sold by a direct sales force or a network of resellers. Telecommunications and ICT providers will be able to create simple and easy quotes and contracts via CloudSense CPQ without the need to rekey orders or engage in manual processes.
CloudBlue will benefit from this new relationship through expanded exposure of its 200+ XaaS digital solutions to the telecommunications community. The initiative clears the way for CloudSense’s customers to access the tools they need to provide businesses of all sizes with the anything-as-a-service (XaaS) offerings that have surged in demand post-pandemic.
“As telcos look for new ways to diversify their offerings, cross-platform integration becomes key to providing end-users the best in Cloud. CloudBlue’s new agreement with CloudSense marks the latest in a series of innovative and creative relationships forming across Cloud to the continued delight of channel partners,” said Tarik Faouzi, senior vice president of CloudBlue.
“CloudSense recognizes the importance of bringing to market innovative solutions that address challenges in our focus verticals. We believe the CloudSense-CloudBlue agreement establishes the first Marketplace of its kind to facilitate commercial innovation across the communications ecosystem. This will give communications service providers broader access to a global network of channel partners and remove the need for manual input when drafting quotes and contracts,” said Jonathan English, CEO, CloudSense.
About CloudSense
The CloudSense Configure, Price, Quote (CPQ) application suite powers increased productivity and profits for ambitious enterprises allowing them to launch faster, sell more and fulfill orders faultlessly. Its growing global community of customers rely on CloudSense to deliver sales transformation within the Communications and Media industries. Leading brands including Telefonica, Telstra, and Informa use CloudSense's portfolio of applications to streamline the entire customer lifecycle, providing a better customer experience while improving business performance. To find out more, visit CloudSense.com
About CloudBlue
CloudBlue helps businesses succeed in the as-a-service economy and accelerate time to revenue by managing subscription and billing, vendor and product information, and partner onboarding across multiple channels. Through its leading ecosystem orchestration platform, CloudBlue enables companies to create their own ecosystems, as well as connect vendor and go-to-market ecosystems, automating the distribution of traditional and digital products and services across partners in the digital supply chain. CloudBlue serves more than 180 companies around the globe and powers the world’s largest cloud B2B marketplaces, which represent 30 million B2B cloud subscriptions. Learn more about CloudBlue at www.cloudblue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005045/en/
Contact information
Andrew Zelinko
CloudBlue
Andrew.Zelinko@cloudblue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom